Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling.
Anmol Sharma,Heena Khan,Thakur Gurjeet Singh,Amarjot Kaur Grewal,Agnieszka Najda,Małgorzata Kawecka-Radomska,Mohamed Kamel,Ahmed E. Altyar,Mohamed M. del-Daim +8 more
Reads0
Chats0
TLDR
A systematic literature review of PubMed, Medline, Bentham, Scopus, and EMBASE (Elsevier) databases was carried out to understand the nature of the extensive work done on modulation of ubiquitin-proteasome pathways in oncogenic signaling as discussed by the authors.Abstract:
The ubiquitin-proteasome pathway (UPP) is involved in regulating several biological functions, including cell cycle control, apoptosis, DNA damage response, and apoptosis. It is widely known for its role in degrading abnormal protein substrates and maintaining physiological body functions via ubiquitinating enzymes (E1, E2, E3) and the proteasome. Therefore, aberrant expression in these enzymes results in an altered biological process, including transduction signaling for cell death and survival, resulting in cancer. In this review, an overview of profuse enzymes involved as a pro-oncogenic or progressive growth factor in tumors with their downstream signaling pathways has been discussed. A systematic literature review of PubMed, Medline, Bentham, Scopus, and EMBASE (Elsevier) databases was carried out to understand the nature of the extensive work done on modulation of ubiquitin-proteasome pathways in oncogenic signaling. Various in vitro, in vivo studies demonstrating the involvement of ubiquitin-proteasome systems in varied types of cancers and the downstream signaling pathways involved are also discussed in the current review. Several inhibitors of E1, E2, E3, deubiquitinase enzymes and proteasome have been applied for treating cancer. Some of these drugs have exhibited successful outcomes in in vivo studies on different cancer types, so clinical trials are going on for these inhibitors. This review mainly focuses on certain ubiquitin-proteasome enzymes involved in developing cancers and certain enzymes that can be targeted to treat cancer.read more
Citations
More filters
Journal ArticleDOI
The Multifaceted Role of Curcumin in Advanced Nanocurcumin Form in the Treatment and Management of Chronic Disorders
Priti Tagde,Pooja Tagde,Fahadul Islam,Sandeep Tagde,Muddaser Shah,Zareen Delawar Hussain,Md. Habibur Rahman,Agnieszka Najda,Ibtesam S. Alanazi,Mousa O. Germoush,Hanan R. H. Mohamed,Mardi M. Algandaby,Mohammed Z. Nasrullah,Natalia Kot,Mohamed M. Abdel-Daim +14 more
TL;DR: In this paper, the authors highlight the therapeutic benefits of nanocurcumin over curcumin and highlight the potential of encapsulating or loading nanocURcumin to increase its therapeutic potential.
Journal ArticleDOI
Mechanistic Insight on Autophagy Modulated Molecular Pathways in Cerebral Ischemic Injury: From Preclinical to Clinical Perspective
TL;DR: An extensive literature search was performed from PubMed, Bentham and Elsevier for various aspects related to molecular mechanisms and pathobiology involved in autophagy and several pre-clinical studies justifiable further in the clinical trials to assist researchers in finding a way to cross the unbridgeable chasm between the pre- clinical and clinical studies.
Journal ArticleDOI
Multiple health benefits of curcumin and its therapeutic potential
TL;DR: In this current review, therapeutic potential of curcumin and its multiple health benefits on various diseases are highlighted.
Journal ArticleDOI
Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway
TL;DR: In this paper , the aberrant expression and biological functions of circRNAs in clear cell renal cell carcinoma (cRCC) remain largely elusive, and the role of circR2A in cancer malignancy is investigated.
References
More filters
Journal ArticleDOI
Regulated protein turnover: snapshots of the proteasome in action.
TL;DR: In a major breakthrough, several groups have determined high-resolution structures of the entire 26S proteasome particle in different nucleotide conditions and with and without substrate using cryo-electron microscopy combined with other techniques, which provide some surprising insights into the functional mechanism of the proteasomes.
Journal ArticleDOI
The ubiquitin-proteasome pathway in cancer
TL;DR: Degradation by the 26S proteasome of specific proteins that have been targeted by the ubiquitin pathway is the major intracellular non-lysosomal proteolytic mechanism and is involved in a broad range of processes, such as cell cycle progression, antigen presentation and control of gene expression.
Journal ArticleDOI
Proteasomes: Machines for All Reasons
TL;DR: The view of the proteasomes is expanded by showing that under certain conditions, proteasome composition can be altered to control ubiquitin homeostasis.
Journal ArticleDOI
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
Marc L. Hyer,Michael Milhollen,Jeff Ciavarri,Fleming Paul E,Tary Traore,Darshan S. Sappal,Jessica Huck,Judy Shi,James M. Gavin,Jim Brownell,Yu Yang,Bradley Stringer,Robert J. Griffin,Frank Bruzzese,Teresa A. Soucy,Jennifer Duffy,Claudia Rabino,Jessica Riceberg,Kara Hoar,Anya Lublinsky,Saurabh Menon,Michael Sintchak,Nancy J. Bump,Sai M Pulukuri,Steve Langston,Stephen Tirrell,Mike Kuranda,Petter Veiby,John Newcomb,Ping Li,Jing Tao Wu,Josh Powe,Lawrence R. Dick,Paul D. Greenspan,Katherine Galvin,Mark Manfredi,Chris Claiborne,Benjamin S. Amidon,Neil F. Bence +38 more
TL;DR: TAK-243 treatment caused death of cancer cells and, in primary human xenograft studies, demonstrated antitumor activity at tolerated doses, allowing for interrogation of ubiquitin biology and for assessment of UAE inhibition as a new approach for cancer treatment.
Journal ArticleDOI
USP1 Deubiquitinates ID Proteins to Preserve a Mesenchymal Stem Cell Program in Osteosarcoma
Samuel A. Williams,Heather Maecker,Dorothy French,Jinfeng Liu,Andrew Gregg,Leah B. Silverstein,Tim C. Cao,Richard A.D. Carano,Vishva M. Dixit +8 more
TL;DR: It is shown that the deubiquitinating enzyme USP1 promotes ID protein stability and stem cell-like characteristics in osteosarcoma, and is identified as a target for differentiation therapy.